| Date | Title | | | 05/02/13 | AtriCure Reports First Quarter 2013 Financial Results| Highlights
Revenue of $19.4 million – up 11.2%; 11.1% constant currency
U.S. sales of $14.6 million – up 11.0%
International sales of $4.8 million – up 11.9%; 11.7% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)--May. 2, 2013--
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
the development of technologies and solutions for the treatment of
atrial fibr... |
|  | | 04/08/13 | AtriCure to Announce First Quarter 2013 Financial Results| WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 8, 2013--
AtriCure, Inc. (Nasdaq:ATRC), a medical device company and a leader in
the development of technologies and solutions for the treatment of
atrial fibrillation, or AF, and systems for the exclusion of the left
atrial appendage, will release its financial results for the first
quarter of 2013 on Thursday, May 2, 2013.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday... |
| | | 03/11/13 | AtriCure Appoints Robert S. White to its Board of Directors| WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 11, 2013--
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems for the treatment of atrial
fibrillation, or AF, and systems for the exclusion of the left atrial
appendage, today announced that Robert “Bob” S. White has been appointed
to the Company’s Board of Directors, effective immediately.
Mr. White is a veteran in the medical technology industr... |
| | | 02/28/13 | AtriCure Reports Fourth Quarter and Full Year 2012 Financial Results|
Highlights
2012 revenue of $70.2 million – up 9.1%
2012 international sales of $17.6 million – up 14.0%
4th quarter revenue of $18.4 million – up 9.5%
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 28, 2013--
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
the development of technologies and solutions for the treatment of
atrial fibrillation, or AF... |
| |
|
